You are here

Article Text

Article menu
Findings that shed new light on the possible pathogenesis of a disease or an adverse effect
A new category for chronic sclerosing sialadenitis as an IgG4 related syndrome
  1. Kazuki Nagai1,
  2. Kazuo Andoh2,
  3. Akira Ogata2,
  4. Noriaki Aoki3,
  5. Noriko Nakamura4,
  6. Hiroo Hosaka5,
  7. Rika Kurihara6
  1. 1Nagai Clinic, Internal Medicine, 1-7-25, Yokodi, Isogo-ku,, Yokohama City, Kanagawa, 2350045, Japan
  2. 2Saiseikai Yokohama City Nanbu Hospital, Radiology, 3-2-10, Konandai, Konan-ku, Yokohama City, Kanagawa, 233-8503, Japan
  3. 3Saiseikai Yokohamashi Nanbu Hospital, Oral and Maxillofacial Surgery, 3-2-10, Konandai, Konan-ku, Yokohama City, 233-8503, Japan
  4. 4Saiseikai Yokohamashi Nanbu Hospital, Pathology, 3-2-10, Konandai, Konan-ku, Yokohama City, 233-8503, Japan
  5. 5Saiseikai Yokohamashi Nanbu Hospital, Internal Medicine, 3-2-10 Kohnandai, kohnan-ku, Yokohama, 234-8503, Japan
  6. 6Kanagawa Dental College, Otolaryngology, 82, Inaokacho, Yokosuka, 238-8580, Japan
  1. Correspondence to Kazuki Nagai, k-nagai{at}mtj.biglobe.ne.jp

Summary

This report presents three cases of IgG4 related sclerosing disease complicated with chronic sclerosing sialadenitis. The clinical, radiographic and pathologic findings later suggested that the patients had chronic sclerosing sialadenitis. The submandibular gland tumour regressed in two patients. These patients were suspected to have Mikulicz’s disease or Sjögren’s syndrome, but the diagnostic criteria were not satisfied. The workup for chronic sclerosing sialadenitis revealed a significantly elevated value of serum IgG4. The patient was then diagnosed with IgG4 related sclerosing disease complicated with chronic sclerosing sialadenitis. After administering prednisolone to these patients, the serum IgG4 values decreased after 4 weeks. The current cases may represent a new category for Mikulicz’s disease or Sjögren’s syndrome as an IgG4 related sclerosing disease.

https://doi.org/10.1136/bcr.10.2009.2412

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests: None.

    • Patient consent: Patient/guardian consent was obtained for publication.